My calculator broke on the third oncology indication….I thought ChatGPT would get me there, but I broke that too when I dropped in ohm's list of potential indications. That must be why they brought in Mr. Hoffman with an extended vesting option period to incentivize and allow him adequate time to complete the valuation calculations for leronlimab!

I’d be happy if he can break the ice with $200M upfront cash and 15% gross sales royalties for the initial oncology indication. This should unlock enough value to put a floor on the stock price in the low single digits, allow us to be eligible for NASDAQ up-listing, allow the company to ramp up trials, and set the stage for leronlimab’s real value to be unlocked. I’m sure some will scoff at this but I think it’s in the range of the most likely scenario for shareholders to get anywhere close to fair valuation for our amazing molecule. I can’t see any BP paying $30B (~$20/share) without more P2+ results and will be difficult for us to get there without a partner IMO. Please prove me wrong Mr. Hoffman!